• Medafor misstatement #1: Sales to CryoLife represent approximately 20% of Medafor's sales and are limited to the cardiac market, only one of many market opportunities available to Medafor. (Source: Second sentence of Paragraph 7, Page 1 of Medafor Letter to Shareholders dated February 10, 2010)
• FACT: CryoLife's contractual rights extend beyond the cardiac field. CryoLife has the exclusive right to sell the MPH product into cardiac and vascular surgeries in the United States (excluding Department of Defense facilities) and into cardiac, vascular and general surgeries in the rest of the World (except China and Japan ) excluding ENT, orthopedic, neurosurgery and topical applications.
Comment: CRY does not address the real issue. More SGA deception. "contractual" and "exclusive" is not an answer. Show me the dollars SGA. They are not broken out on CRY's financial statement. More SGA "BS", at least that is what we call it in Minnesota. The lack of substance in CRY's response is exactly why Medafor does not want any part of CRY.
CRY says that anything Medafor says is a "misrepresentation", while what they say is "fact". Judge, jury, God, and SGA are apparently the same thing? This is just a SGA pissing contest. Not much substance. A lot of "BS". All from a boy from the east side of St. Paul too.